01 / Monoclonal antibodies
Investigating a CHO process transfer across manufacturing sites
A transfer investigation connecting matched batch cohorts, temperature-transition timing and a product-specific quality panel.
ENTERPRISE USE CASES / EIGHT MODALITIES
Different process questions.
A clearer path to a decision.
Explore how connected evidence, scientific analysis and expert review can support enterprise investigations across programs, sites and partners.
10 modality workflows + 6 Twin use casesScientific reasoning & decision pathsExplore the use cases ↓
These are proposed enterprise workflows, not measured customer outcomes. Integration, model suitability and review behavior are verified for the intended deployment.
02 / Microbial fermentation
Separating fermentation productivity loss from recovery loss
An enterprise investigation reconciling assay basis, production-phase accounting and recovery performance across a fermentation network.
03 / Chemical & pharmaceutical APIs
Investigating an API impurity shift after CDMO transfer
A route-step investigation separating analytical-method effects, reaction execution and impurity behavior through isolation.
04 / Recombinant proteins
Preserving protein activity through enterprise purification
An expression-to-purification investigation that separates recovered protein mass from retained biological activity.
05 / Cell therapies
Separating starting-material variability from cell-process performance
An autologous cell-therapy development use case connecting material attributes, stage performance, viable yield and product-specific potency.
06 / Gene therapies / AAV
Reconciling vector yield, recovery and potency across AAV campaigns
A vector-process use case connecting production, fraction recovery, capsid attributes, genome evidence and functional assessment.
07 / RNA & oligonucleotides
Balancing oligonucleotide purity and recovery across synthesis campaigns
A synthetic ASO-focused use case connecting sequence/process context, impurity characterization and purification pooling.
08 / Viral vaccines
Editorial date
Investigating vaccine harvest and recovery variability
Connect campaign, assay and recovery evidence to separate an upstream signal from a downstream loss or measurement difference.
09 / mAb / CHO development
Editorial date
Balancing mAb titer and quality from the next experiment to scale-up
Follow a CHO fed-batch development decision from strong titer and variable quality through experiment selection, a pilot-scale surprise and a targeted confirmation plan.
10 / MSAT · Monoclonal antibodies
Editorial date
From Batch Variability to Predictable Biomanufacturing
How BioMedAna helps MSAT teams investigate batch variability, assess process risks and evaluate manufacturing scenarios using scientific models and AI.
BIOMEDANA TWIN USE CASES
From the next scale to the next capacity decision.
Explore process-model workflows and scoped engineering engagements for facility and line decisions.
TWIN 01 / BIOLOGICS SCALE-UP
Editorial date
Choose the next scale with engineering evidence
Compare candidate vessel conditions against oxygen transfer, mixing and process-performance evidence before committing an engineering run.
Engagement basis: Project-data process model and engineering assessment
TWIN 02 / TECHNOLOGY TRANSFER
Editorial date
Make the receiving-site transfer decision explicit
Connect sending-site history, receiving-asset differences and bounded model comparisons to focus the next transfer study.
Engagement basis: Project-data comparison and process-model evaluation
TWIN 03 / RECOVERY & OPERATING WINDOWS
Editorial date
Find the process change worth testing next
Compare upstream performance, purification recovery and explicit cost assumptions to choose a better-supported process experiment.
Engagement basis: Process-train scenario evaluation
TWIN 04 / FACILITY READINESS & RAMP-UP
Editorial date
Connect a new CDMO facility’s design basis to ramp-up evidence
Use a staged evidence and modeling program to compare design assumptions, commissioning results and early operating constraints.
Engagement basis: Scoped engineering engagement with project-specific facility models
TWIN 05 / LINE PERFORMANCE & CAPACITY
Editorial date
Locate the constraint behind fill-finish and packaging capacity
Frame the evidence and simulation needed to compare throughput losses, changeovers, buffers and product mix across a sterile line.
Engagement basis: Scoped line-modeling engagement and source-system integration
TWIN 06 / SINGLE-USE TO STAINLESS STEEL
Editorial date
Evaluate a 2,000 L single-use to 10,000 L stainless-steel scale-up
Connect the development baseline, vessel engineering and product-quality evidence to decide which large-scale scenario deserves physical confirmation.
Engagement basis: Project-specific CHO fed-batch process model, equipment assessment and staged scientific validation
8 MODALITIES · ONE GOVERNED FOUNDATION
Coordinate the work across modalities.
Keep the process question, source evidence and model scope connected as agents prepare analyses and next steps for expert review. Vaccine workflows carry infection, harvest and inactivation context through the same foundation.
CHO · mAbMonoclonal antibodies↗CHO · MicrobialRecombinant proteins↗CAR-T · TIL · NKCell therapies↗AAV · LentiviralGene therapies and viral vectors↗Bacterial · YeastMicrobial and precision fermentation↗ASO · siRNARNA and oligonucleotides↗Small molecule · Reaction kineticsChemical & pharmaceutical APIs↗VAX · Cell cultureViral vaccines↗
Workflow availability and model suitability are evaluated for the product, process and intended use. Scientific and quality decisions remain with your team.
START WITH YOUR QUESTION
Make the next investigation
specific to your process.
Bring the decision, its owner and the evidence available. We will map the workflow and the review criteria together.
Discuss your use case ↗